<DOC>
	<DOCNO>NCT00268242</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine mitoxantrone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give gemcitabine together mitoxantrone work treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Gemcitabine Mitoxantrone Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response ( CR ) rate ( CR incomplete blood count recovery ( CRi ) ) patient acute myeloid leukemia first relapse treat gemcitabine hydrochloride mitoxantrone hydrochloride . Secondary - Evaluate disease free overall survival patient acute myeloid leukemia first relapse treat particular chemotherapy regimen . - Assess hematologic non-hematologic toxicity associate regimen . - Assess laboratory correlate drug resistance patient relapse acute myeloid leukemia . - Assess percentage patient receive subsequent bone marrow transplantation . OUTLINE : This open-label , multicenter study . Patients receive gemcitabine hydrochloride IV 12 hour day 1 mitoxantrone hydrochloride IV 30-60 minute day 1 , 2 , 3 . After completion single course therapy , patient achieve complete response may receive 1 additional course therapy discretion treat physician . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Bone marrow examination peripheral blood analysis confirm active acute myeloid leukemia WHO criteria No M3 acute myeloid leukemia Not candidate allogenic bone marrow transplantation Patient must first relapse receive induction chemotherapy Received 1 2 course remission last least 1 month Patients chloromas leukemia cutis eligible No evidence leptomeningeal involvement PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Liver enzyme ( total bilirubin , aspartate aminotransferase ( AST ) ALT ) ≤ 2.5 time upper limit normal Liver enzymes ≥ 2.5 acceptable physician document secondary disease Serum creatinine ≤ 3 mg/dL No poorly control medical condition would seriously complicate compliance study No active primary malignancy carcinoma situ cervix basal cell carcinoma skin No New York Heart Association grade III IV cardiac problem , define congestive heart failure myocardial infarction within 6 month prior start study Pregnant nursing woman ineligible Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No documented history human immunodeficiency virus ( HIV ) infection No history chronic liver disease Ejection fraction ≥ 45 % No significant history noncompliance medical regimen inability give reliable inform consent PRIOR CONCURRENT THERAPY : Previous treatment related toxicity resolve grade 1 good No investigational agent within 14 day prior start study No chemotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior start study No major surgery within 2 week prior start study At least two week must elapse since conclusion radiation therapy start gemcitabine hydrochloride , provide acute effect radiation treatment resolve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>